Genetics

Prof. Emerita Mary-Lou Pardue, a cellular and molecular biologist whose work “formed the foundation for key advancements and discoveries in understanding the structure of chromosomes,” has died at age 90, reports Bryan Marquard for The Boston Globe. Pardue “was a role model of what women in science can be at a time when there weren’t a lot of those, and a trailblazer as a woman,” emphasizes Ky Lowenhaupt, manager of the Biophysical Instrumentation Facility at MIT, “but also a trailblazer as a scientist who didn’t do things along the path that other people took.”

Sonia Vallabh and Eric Minikel, senior group leaders from the Broad Institute have created a gene-editing tool to combat prion diseases, reports Karen Weintraub for USA Today. The approach “should also work against diseases such as Huntington's, Parkinson's, ALS and even Alzheimer's, which result from the accumulation of toxic proteins,” Weintraub writes.

MIT researchers have created an amber-like material that preserves DNA so it can store data, improving on current methods that use particles of silica or require freezing, reports Pandora Dewan for Newsweek. The team “demonstrated their material by embedding and subsequently removing a DNA sequence encoding the music for the Jurassic Park theme song,” Dewan explains. “Following this process, they sequenced the molecule and confirmed that no errors had been introduced into the DNA sequence.”

MIT researchers have discovered a protein found in human sweat that holds antimicrobial properties and can “inhibit the growth of the bacteria that causes Lyme disease,” reports Matt Fortin for NENC. The team believes this “type of protein could be put into a topical cream to make something called ‘Lyme Block’ – like sunblock, but for preventing Lyme.”  "Ideally what we would love to do is give people more control over their own risk," says Principal Research Scientist Michal Tal. "And really try to develop this into a possible preventative that you could put on repellant or sunblock to protect against other elements of the outdoors that you could also protect yourself against Lyme."

Researchers from MIT and elsewhere have isolated a “protein in human sweat that protects against Lyme disease,” reports Matthew Rozsa for Salon. The researchers believe that if “properly harnessed the protein could form the basis of skin creams that either prevent the disease or treat especially persistent infections,” writes Rosza.

Ashley Smart, associate director of the Knight Science Journalism Program, writes for Undark about the impact of commercialized genetic tests on research involving new genetic links. “Even among some researchers who are optimistic about using polygenic scores to screen for physical health conditions, there is one emerging application of polygenic scores that makes them uneasy: the prediction of risks for depression and other psychiatric conditions,” writes Smart.

Researchers at MIT and elsewhere have identified key cell types that may protect the brain against Alzheimer’s symptoms, reports Sara Reardon for Nature. “Most Alzheimer’s research has focused on excitatory neurons, which relay electrical signals to activate other neurons,” explains Reardon. “But the authors found that the cells with reelin or somatostatin were inhibitory neurons, which halt neuronal communication. These inhibitory cells might therefore have a previously unknown role in the types of cognitive function that are lost during Alzheimer’s.”

Writing for The Washington Post, research affiliate Bina Venkataraman emphasizes that “if biomedical breakthroughs are to benefit the millions of children afflicted with rare diseases, genetic testing of babies needs to expand.” Venkataraman adds: “By screening newborn genomes for currently known genetic diseases, patients and scientists could gain insights that lead to the treatment and prevention of thousands of illnesses that currently lack cures.”

MIT researchers have discovered an RNA-guided DNA-cutting enzyme in eukaryotes, reports Science. “The researchers speculate that eukaryotic cells may have gained the newly identified editing genes from transposable elements—so-called jumping genes—they received from bacteria,” writes Science.

MIT researchers have identified a new biological editing system that could “potentially be even more precise than CRISPR gene editing,” reports Laura Baisas for Popular Science. The new system, based on a protein called Fanzor, is “the first programmable RNA-guided system discovered in eukaryotes,” Baisas notes.

In a new study, researchers at MIT showed that they “were able to interfere with an enzyme typically found to be overactive in the brains of Alzheimer’s patients,” reports Alex Mitchell for The New York Post. After using a peptide to treat the overactive enzyme, they found that “the peptide shows protective effects against loss of neurons and also appears to be able to rescue some of the behavior deficits,” says Prof. Li-Huei Tsai.

Boston Globe reporter Ryan Cross spotlights Chroma Medicine, a biotech startup co-founded by MIT researchers that is “developing a new class of gene editing technologies that could control how our genetic code is read without changing the code itself.” Cross explains that Chroma Medicine’s technology could “have broad applications for treating both rare and common diseases.”

Researchers at MIT have found that those with an E4 variant display abnormalities in cholesterol metabolism, reports William A. Haseltine for Forbes. “The MIT team suggest that the disruption of cholesterol metabolism could be a fundamental reason why those with the E4 variant are more likely to develop Alzheimer’s disease symptoms,” writes Haseltine.

Lydia Villa Komaroff PhD ’75 speaks with NPR reporter Emily Kwong about her work in gene editing. Biotechnology and genetic engineering were “enormously impactful,” says Komaroff. “So impactful that molecular biology pretty much disappeared as a field, it has become a tool that is of use in every field of biology and medicine today.”

An MIT research study suggests that those with the E4 variant of the APOE gene are more likely to develop Alzheimer’s symptoms, reports William A. Haseltine for Forbes. The variant “disrupts how fat molecules are processed in the brain,” writes Haseltine. “It appears that the disruption of these fat molecules could be the fundamental reason why those that contain the E4 variant are more likely to develop Alzheimer’s symptoms.”